Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression
3 June 2015 | By Victoria White
Results from an interim analysis of the Phase III ELOQUENT-2 trial of elotuzumab in combination with lenalidomide and dexamethasone have been announced...